Boehringer Ingelheim acquires GST to expand stem cell capabilities

By Nikita Chaurasia  | Date: 2020-07-29

Boehringer Ingelheim acquires GST to expand stem cell capabilities

Boehringer Ingelheim, a leader in pharmaceutical products, has recently made it to the headlines by acquiring Belgium-based veterinary biotech firm, Global Stem cell Technology (GST).

According to reliable sources, the collaboration with GST will allow Boehringer to expand its development pipeline, while parallelly focusing on setting higher standards of animal healthcare. However, the financial details of the deal were not disclosed.

The two companies had initially partnered in the year 2018 and had launched a stem cell product, Arti-Cell® Forte in 2019.  Arti-Cell® Forte is apparently the first stem cell product which was granted marketing authorization by the European commission in the veterinary domain.

Boehringer Ingelheim Animal Health’s Head of Global Strategic Marketing Jean-Luc Michel, was reported stating that the company had finally decided to acquire GST after two years of partnership which will help in expanding Boehringer Ingelheim’s portfolio. He added that GST’s expertise in stem cell production will allow Boehringer to  deliver advanced and innovative solutions to their clients.

Jan Spaas CEO of GST mentioned that that Boehringer Ingelheim’s mission to lead a new wave of development and innovation in the veterinary industry complies with GST vision. He further claimed that GST will operate as a new research and development division Boehringer’s banner.

For those uninitiated, Boehringer Ingelheim Animal Health is one of the largest animal health businesses in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 countries.

On the other hand, Global Stem cell Technology (GST) is a biotech company with primary focus on R&D activities and manufacture of veterinary stem cell-based products.

In other news, Boehringer Ingelheim had recently teamed up with Biognosys to enhance next-gen proteomics applications for drug development and discovery.

Source credits: https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-acquires-global-stem-cell-technology

https://www.news-medical.net/news/20200724/Boehringer-Ingelheim-and-Biognosys-join-forces-on-applying-quantitative-proteomics-tools-in-drug-discovery.aspx

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Swiftly achieves Unicorn status with $100M Series C led by BRV Capital

Swiftly achieves Unicorn status with $100M Series C led by BRV Capital

By Nikita Chaurasia

Swiftly Systems has reportedly achieved unicorn status, securing in funding through a Series C round. The prominent BRV Capital Management led this funding initiative. According to the earlier reports, Swiftly was adopted by hundreds of consumer b...

Rainforest nations unify to demand cash for climate & biodiversity preservation

Rainforest nations unify to demand cash for climate & biodiversity preservation

By Nikita Chaurasia

As per the reports, twelve nations with rainforests united to establish a collective initiative aiming to address climate change and safeguard biodiversity at summit held in Brazil. The declaration, titled "United for Our Forests," emerged ...

AI Chatbot, Llama 2, unveiled by Meta for commercial use via Microsoft

AI Chatbot, Llama 2, unveiled by Meta for commercial use via Microsoft

By Nikita Chaurasia

Meta Platforms has recently introduced Llama 2, an artificial intelligence large language model, for commercial use in collaboration with major cloud providers like Microsoft. Instead of charging for access or usage, Meta aims to share the model with...

Moderna signs agreement to explore mRNA medicines in China

Moderna signs agreement to explore mRNA medicines in China

By Nikita Chaurasia

Moderna Inc, a leading vaccine manufacturer, reportedly announced on Wednesday that it has entered into a memorandum of understanding (MoU) and a land collaboration agreement aimed at exploring opportunities for researching, developing, and producing...

Nike and Epic Games collaborate to launch Airphoria NFT in Fortnite

Nike and Epic Games collaborate to launch Airphoria NFT in Fortnite

By Nikita Chaurasia

The American footwear design & manufacturing company, Nike and Epic Games, the creators of the popular online game Fortnite, have joined forces in an exciting new collaboration. The partnership aims to bring about a groundbreaking change in the d...